{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T22:31:56Z","timestamp":1781303516649,"version":"3.54.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T00:00:00Z","timestamp":1766793600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000066","name":"U.S. Department of Health & Human Services | NIH | National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","award":["R35 ES030443"],"award-info":[{"award-number":["R35 ES030443"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000066","name":"U.S. Department of Health & Human Services | NIH | National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","award":["P42 ES004699"],"award-info":[{"award-number":["P42 ES004699"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["505561502"],"award-info":[{"award-number":["505561502"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    While the hydrolase activity of soluble epoxide hydrolase (sEH) reduces vascular calcification, it is not known whether the phosphatase activity of sEH (sEH-P) is also involved. Pharmacological and genetic inhibition of sEH-P reduced the increased calcium deposition in rat aortic rings cultured under high-phosphate conditions. This was associated with decreased mRNA expression of the osteochondrogenic markers\n                    <jats:italic>Msx2<\/jats:italic>\n                    and\n                    <jats:italic>Sox9<\/jats:italic>\n                    . Deendothelialization of the aortic rings abolished this anticalcifying effect, while the calcification of human aortic smooth muscle cells was unaffected by sEH-P inhibition, suggesting a predominant role of the endothelium. Endothelial NO release did not appear to contribute, but an increased level of the calcification inhibitor pyrophosphate anions (PPi) was observed in the culture supernatant of aortic rings when sEH-P was inhibited. In vitro experiments demonstrated that PPi is a substrate of sEH-P, and that inhibiting sEH-P prevented the high-phosphate induced decrease of PPi in human aortic endothelial cells. Furthermore, the aortic calcification related to chronic kidney disease induced by subtotal nephrectomy was reduced in sEH-P-deficient rats compared to wild-type rats. This was associated with an improvement in flow-induced isolated mesenteric artery dilatation and a reduction of cardiac hypertrophy and fibrosis. Vascular calcification is regulated by sEH-P through the metabolism of endothelial PPi. The prevention of vascular calcification, together with the reduction in vascular dysfunction and cardiac remodeling, suggests that inhibiting sEH-P may help to prevent the cardiovascular complications associated with chronic kidney disease.\n                  <\/jats:p>","DOI":"10.1038\/s41419-025-08390-6","type":"journal-article","created":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T13:33:13Z","timestamp":1766842393000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The phosphatase activity of soluble epoxide hydrolase regulates vascular calcification through the metabolism of pyrophosphate anions"],"prefix":"10.1038","volume":"17","author":[{"given":"Hind","family":"Messaoudi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Varennes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Perzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvanie","family":"Renet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghiles","family":"Chegrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Duflot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Feugray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix F.","family":"Lillich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Kauffenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9ry","family":"Brunel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Six","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romuald","family":"Mentaverri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Anegon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Morisseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa\u00efd","family":"Kamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewgenij","family":"Proschak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0383-2342","authenticated-orcid":false,"given":"J\u00e9r\u00e9my","family":"Bellien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,27]]},"reference":[{"key":"8390_CR1","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1161\/CIRCRESAHA.110.234914","volume":"109","author":"CM Shanahan","year":"2011","unstructured":"Shanahan CM, Crouthamel MH, Kapustin A, Giachelli CM. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res. 2011;109:697\u2013711.","journal-title":"Circ Res"},{"key":"8390_CR2","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.tcm.2014.10.021","volume":"25","author":"JA Leopold","year":"2015","unstructured":"Leopold JA. Vascular calcification: mechanisms of vascular smooth muscle cell calcification. Trends Cardiovasc Med. 2015;25:267\u201374.","journal-title":"Trends Cardiovasc Med"},{"key":"8390_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.vph.2016.05.014","volume":"84","author":"KI Bostr\u00f6m","year":"2016","unstructured":"Bostr\u00f6m KI. Where do we stand on vascular calcification?. Vascul Pharmacol. 2016;84:8\u201314.","journal-title":"Vascul Pharmacol"},{"key":"8390_CR4","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.3390\/ijms21082685","volume":"21","author":"SJ Lee","year":"2020","unstructured":"Lee SJ, Lee IK, Jeon JH. Vascular calcification-new insights into its mechanism. Int J Mol Sci. 2020;21:2685.","journal-title":"Int J Mol Sci"},{"key":"8390_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2011.03.015","volume":"131","author":"J Bellien","year":"2011","unstructured":"Bellien J, Joannides R, Richard V, Thuillez C. Modulation of cytochrome-derived epoxyeicosatrienoic acids pathway: a promising pharmacological approach to prevent endothelial dysfunction in cardiovascular diseases?. Pharmacol Ther. 2011;131:1\u201317.","journal-title":"Pharmacol Ther"},{"key":"8390_CR6","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.prostaglandins.2017.07.002","volume":"133","author":"J Kramer","year":"2017","unstructured":"Kramer J, Proschak E. Phosphatase activity of soluble epoxide hydrolase. Prostaglandins Other Lipid Mediat. 2017;133:88\u201392.","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"8390_CR7","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1146\/annurev-pharmtox-011112-140244","volume":"53","author":"C Morisseau","year":"2013","unstructured":"Morisseau C, Hammock BD. Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health. Annu Rev Pharmacol Toxicol. 2013;53:37\u201358.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"8390_CR8","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.bbrc.2012.02.108","volume":"419","author":"C Morisseau","year":"2012","unstructured":"Morisseau C, Schebb NH, Dong H, Ulu A, Aronov PA, Hammock BD. Role of soluble epoxide hydrolase phosphatase activity in the metabolism of lysophosphatidic acids. Biochem Biophys Res Commun. 2012;419:796\u2013800.","journal-title":"Biochem Biophys Res Commun"},{"key":"8390_CR9","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jare.2022.03.004","volume":"43","author":"M Leuillier","year":"2023","unstructured":"Leuillier M, Duflot T, M\u00e9noret S, Messaoudi H, Djerada Z, Groussard D, et al. CRISPR\/Cas9-mediated inactivation of the phosphatase activity of soluble epoxide hydrolase prevents obesity and cardiac ischemic injury. J Adv Res. 2023;43:163\u201374.","journal-title":"J Adv Res"},{"key":"8390_CR10","doi-asserted-by":"publisher","first-page":"4313","DOI":"10.3390\/ijms21124313","volume":"21","author":"O Varennes","year":"2020","unstructured":"Varennes O, Mentaverri R, Duflot T, Kauffenstein G, Objois T, Lenglet G, et al. The metabolism of epoxyeicosatrienoic acids by soluble epoxide hydrolase is protective against the development of vascular calcification. Int J Mol Sci. 2020;21:4313.","journal-title":"Int J Mol Sci"},{"key":"8390_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04283-6","volume":"12","author":"W He","year":"2021","unstructured":"He W, Huang J, Liu Y, Xie C, Zhang K, Zhu X, et al. Deletion of soluble epoxide hydrolase suppressed chronic kidney disease-related vascular calcification by restoring Sirtuin 3 expression. Cell Death Dis. 2021;12:992.","journal-title":"Cell Death Dis"},{"key":"8390_CR12","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1161\/01.CIR.0000109487.46725.02","volume":"109","author":"M Fornage","year":"2004","unstructured":"Fornage M, Boerwinkle E, Doris PA, Jacobs D, Liu K, Wong ND. Polymorphism of the soluble epoxide hydrolase is associated with coronary artery calcification in African-American subjects: The Coronary Artery Risk Development in Young Adults (CARDIA) study. Circulation. 2004;109:335\u20139.","journal-title":"Circulation"},{"key":"8390_CR13","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3132\/dvdr.2008.021","volume":"5","author":"KP Burdon","year":"2008","unstructured":"Burdon KP, Lehtinen AB, Langefeld CD, Carr JJ, Rich SS, Freedman BI, et al. Genetic analysis of the soluble epoxide hydrolase gene, EPHX2, in subclinical cardiovascular disease in the Diabetes Heart Study. Diab Vasc Dis Res. 2008;5:128\u201334.","journal-title":"Diab Vasc Dis Res"},{"key":"8390_CR14","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.dmpk.2014.09.002","volume":"30","author":"ER Purba","year":"2015","unstructured":"Purba ER, Leuhery EA, Oguro A, Imaoka S. The metabolism of lysophosphatidic acids by allelic variants of human soluble epoxide hydrolase. Drug Metab Pharmacokinet. 2015;30:75\u201381.","journal-title":"Drug Metab Pharmacokinet"},{"key":"8390_CR15","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.bbrc.2005.12.180","volume":"341","author":"AE Enayetallah","year":"2006","unstructured":"Enayetallah AE, Grant DF. Effects of human soluble epoxide hydrolase polymorphisms on isoprenoid phosphate hydrolysis. Biochem Biophys Res Commun. 2006;341:254\u201360.","journal-title":"Biochem Biophys Res Commun"},{"key":"8390_CR16","doi-asserted-by":"publisher","first-page":"8443","DOI":"10.1021\/acs.jmedchem.9b00445","volume":"62","author":"JS Kramer","year":"2019","unstructured":"Kramer JS, Woltersdorf S, Duflot T, Hiesinger K, Lillich FF, Kn\u00f6ll F, et al. Discovery of the first in vivo active inhibitors of the soluble epoxide hydrolase phosphatase domain. J Med Chem. 2019;62:8443\u201360.","journal-title":"J Med Chem"},{"key":"8390_CR17","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1093\/cvr\/cvr267","volume":"93","author":"HH Hou","year":"2012","unstructured":"Hou HH, Hammock BD, Su KH, Morisseau C, Kou YR, Imaoka S, et al. N-terminal domain of soluble epoxide hydrolase negatively regulates the VEGF-mediated activation of endothelial nitric oxide synthase. Cardiovasc Res. 2012;93:120\u20139.","journal-title":"Cardiovasc Res"},{"key":"8390_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/srep13524","volume":"5","author":"HH Hou","year":"2015","unstructured":"Hou HH, Liao YJ, Hsiao SH, Shyue SK, Lee TS. Role of phosphatase activity of soluble epoxide hydrolase in regulating simvastatin-activated endothelial nitric oxide synthase. Sci Rep. 2015;5:13524.","journal-title":"Sci Rep"},{"key":"8390_CR19","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1089\/ten.teb.2012.0527","volume":"19","author":"TM Liu","year":"2013","unstructured":"Liu TM, Lee EH. Transcriptional regulatory cascades in Runx2-dependent bone development. Tissue Eng Part B Rev. 2013;19:254\u201363.","journal-title":"Tissue Eng Part B Rev"},{"key":"8390_CR20","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/cvr\/cvm049","volume":"77","author":"Y Kanno","year":"2008","unstructured":"Kanno Y, Into T, Lowenstein CJ, Matsushita K. Nitric oxide regulates vascular calcification by interfering with TGF-signalling. Cardiovasc Res. 2008;77:221\u201330.","journal-title":"Cardiovasc Res"},{"key":"8390_CR21","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1093\/cvr\/cvw062","volume":"110","author":"I Alesutan","year":"2016","unstructured":"Alesutan I, Feger M, Tuffaha R, Castor T, Musculus K, Buehling SS, et al. Augmentation of phosphate-induced osteo-\/chondrogenic transformation of vascular smooth muscle cells by homoarginine. Cardiovasc Res. 2016;110:408\u201318.","journal-title":"Cardiovasc Res"},{"key":"8390_CR22","first-page":"363","volume":"35","author":"D Schibler","year":"1968","unstructured":"Schibler D, Russell RG, Fleisch H. Inhibition by pyrophosphate and polyphosphate of aortic calcification induced by vitamin D3 in rats. Clin. Sci. 1968;35:363\u201372.","journal-title":"Clin. Sci"},{"key":"8390_CR23","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/ki.2010.461","volume":"79","author":"WC O\u2019Neill","year":"2011","unstructured":"O\u2019Neill WC, Lomashvili KA, Malluche HH, Faugere MC, Riser BL. Treatment with pyrophosphate inhibits uremic vascular calcification. Kidney Int. 2011;79:512\u20137.","journal-title":"Kidney Int"},{"key":"8390_CR24","doi-asserted-by":"publisher","first-page":"13536","DOI":"10.3390\/ijms222413536","volume":"22","author":"R Villa-Bellosta","year":"2021","unstructured":"Villa-Bellosta R. Vascular calcification: key roles of phosphate and pyrophosphate. Int J Mol Sci. 2021;22:13536.","journal-title":"Int J Mol Sci"},{"key":"8390_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.759359","volume":"12","author":"JLE Wimmer","year":"2021","unstructured":"Wimmer JLE, Kleinermanns K, Martin WF. Pyrophosphate and irreversibility in evolution, or why PPi is not an energy currency and why nature chose triphosphates. Front Microbiol. 2021;12:759359.","journal-title":"Front Microbiol"},{"key":"8390_CR26","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41392-020-00367-5","volume":"6","author":"LHM Geraldo","year":"2021","unstructured":"Geraldo LHM, Spohr TCLS, Amaral RFD, Fonseca ACCD, Garcia C, Mendes FA, et al. Role of lysophosphatidic acid and its receptors in health and disease: novel therapeutic strategies. Signal Transduct Target Ther. 2021;6:45.","journal-title":"Signal Transduct Target Ther"},{"key":"8390_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2023.116868","volume":"176","author":"LE Bourne","year":"2023","unstructured":"Bourne LE, Davies BK, Millan JL, Arnett TR, Wheeler-Jones CPD, Keen JAC, et al. Evidence that pyrophosphate acts as an extracellular signalling molecule to exert direct functional effects in primary cultures of osteoblasts and osteoclasts. Bone. 2023;176:116868.","journal-title":"Bone"},{"key":"8390_CR28","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.3390\/jcm12041539","volume":"12","author":"H Messaoudi","year":"2023","unstructured":"Messaoudi H, Levesque T, Perzo N, Berg E, Feugray G, Dumesnil A, et al. Subtotal nephrectomy associated with a high-phosphate diet in rats mimics the development of calcified aortic valve disease associated with chronic renal failure. J Clin Med. 2023;12:1539.","journal-title":"J Clin Med"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08390-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08390-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08390-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T17:00:58Z","timestamp":1769533258000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08390-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,27]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8390"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-08390-6","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,27]]},"assertion":[{"value":"25 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"143"}}